PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Upadacitinib - Inflammatory bowel disease

PAD Profile : Upadacitinib - Inflammatory bowel disease Important

Keywords :
IBD, Ulcerative colitis, UC, Crohn's disease, high cost immunomodulator, Sequential use of biologic medicines , JAK inhibitor, Janus Kinase, Jakinib
Brand Names Include :
Rinvoq
Important Information :
Ulcerative colitis in Adults only.

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Modified release tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.

02 August 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

CROHN'S DISEASE

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends upadacitinib for previously treated moderately to severely active Crohn’s Disease in line with NICE TA905.

Upadacitinib will be given a RED traffic light status for this indication. Prescribing will be by hospital specialists only, in line with NICE TA905.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

01 March 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

ULCERATIVE COLITIS

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends upadacitinib as a treatment option for the treatment of moderately to severely active Ulcerative Colitis in line with NICE TA856

Upadacitinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA856.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More